TheraCryf (LSE:TCF) Other Operating Expense: £2.24 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TheraCryf Other Operating Expense?

TheraCryf LSE:TCF Other Operating Expense is £2.24 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

TheraCryf's Other Operating Expense for the six months ended in Sep. 2025 was £1.37 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 was £2.24 Mil.

TheraCryf's quarterly Other Operating Expense declined from Sep. 2024 (£1.25 Mil) to Mar. 2025 (£0.87 Mil) but then increased from Mar. 2025 (£0.87 Mil) to Sep. 2025 (£1.37 Mil).

TheraCryf's annual Other Operating Expense declined from Mar. 2023 (£1.41 Mil) to Mar. 2024 (£0.16 Mil) and declined from Mar. 2024 (£0.16 Mil) to Mar. 2025 (£0.13 Mil).

TheraCryf Other Operating Expense Historical Data

* Premium members only.

The historical data trend for TheraCryf's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf Other Operating Expense Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 0.16 1.41 0.16 0.13

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 2.10 1.25 0.87 1.37

TheraCryf Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £2.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of £2.24 Mil mean?
TheraCryf (LSE:TCF) has a Other Operating Expense of £2.24 Mil as of Sep. 2025. Other operating expenses that a company records on its income statement. View historical data on TheraCryf and its competitors.
Is TheraCryf's Other Operating Expense too high?
TheraCryf's current Other Operating Expense is £2.24 Mil.
How does TheraCryf's Other Operating Expense compare to VRTX and REGN?
TheraCryf's Other Operating Expense of £2.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on TheraCryf and its competitors. TheraCryf's current Other Operating Expense is £2.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current Other Operating Expense of £2.24 Mil. The current Other Operating Expense is £2.24 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current Other Operating Expense is £2.24 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.